FAQ

7-ethyl-10-hydroxycamptothecin glucuronide

Known as: SN-38 glucuronide 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1993-2017
051019932017

Related topics

Related topics

3 relations

Broader (2)

CamptothecinGlucuronides
analogs & derivatives

Related mentions per year

Related mentions per year

1937-2018
19401960198020002020
7-ethyl-10-hydroxycamptothecin glucuronide
Camptothecin
Glucuronides
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.
PURPOSE We aim to identify genetic variation, in addition to the UGT1A1*28 polymorphism, that can explain the variability in… (More)
  • figure 1
  • table 1
  • table 1
  • table 2
  • table 2
Is this relevant?
2008
2008
Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.
The coadministration of protease inhibitors with anticancer drugs in the management of human immunodeficiency virus-related… (More)
Is this relevant?
2006
2006
Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer.
Pharmacogenetic testing for UDP-glucuronosyltransferase (UGT) 1A1*28, a promoter variant of the UGT1A1 gene, is now carried out… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
The metabolism of irinotecan (CPT-11) involves sequential activation to SN-38 and detoxification to the pharmacologically… (More)
  • figure 1
  • table 1
  • figure 2
Is this relevant?
2002
2002
The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites.
Irinotecan hydrochloride (CPT-11) is an anticancer agent with unpredictable bouts of diarrhea as a dose-limiting toxic side… (More)
Is this relevant?
2002
2002
Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide.
OBJECTIVE The objective of the study was to develop and validate a population pharmacokinetic model for irinotecan and 2 of its… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients.
This study determined the disposition of irinotecan hydrochloride trihydrate (CPT-11) after i.v. infusion of 125 mg/m(2) (100… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Irinotecan therapy in adults with recurrent or progressive malignant glioma.
PURPOSE To determine the activity, toxicity, and pharmacokinetics of irinotecan (CPT-11, Camptosar; Pharmacia & Upjohn, Kalamazoo… (More)
Is this relevant?
1996
1996
Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity.
PURPOSE To construct limited-sampling models (LSMs) for irinotecan (CPT-11) pharmacokinetic (PK) measures. MATERIALS AND… (More)
Is this relevant?
1993
1993
Inhibition of beta-glucuronidase by natural glucuronides of kampo medicines using glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a substrate.
1. 7-Ethyl-10-[4-(piperidino)-1-piperidino] carbonyloxycamptothecin (CPT-11), a potent anticancer agent currently under… (More)
Is this relevant?